Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer.
Min Hee HongHye Ryun KimBeung Chul AhnSu Jin HeoJi Hyoung KimByoung Chul ChoPublished in: Yonsei medical journal (2019)
Approximately 60% of patients in the analyzed real-world cohort were eligible for tissue rebiopsy upon NSCLC progression. Osimertinib activity was higher in patients in whom T790M mutations were detected in tissues rather than in plasma samples.
Keyphrases
- drug resistant
- small cell lung cancer
- end stage renal disease
- ejection fraction
- chronic kidney disease
- multidrug resistant
- prognostic factors
- epidermal growth factor receptor
- gene expression
- advanced non small cell lung cancer
- acinetobacter baumannii
- patient reported outcomes
- tyrosine kinase
- pseudomonas aeruginosa
- brain metastases